ReproCell

ReproCell Long-Term Investments

The Long-Term Investments of ReproCell (4978.T) as of Oct 19, 2026 is 996.00 M JPY. In the previous year, Long-Term Investments was 544.00 M JPY — a change of 83.09% (higher).

Long-Term Investments

996.00 MJPY

YoY

83.09%

Last updated:

Long-Term Investments of ReproCell is 2019 996.00 M JPY. Long-Term Investments of ReproCell was 2018 544.00 M JPY. It decreases by 83.09% higher compared to the previous year.

The ReproCell Long-Term Investments history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-Term Investments
Date
Long-Term Investments
Jan 1, 2015
78.00 M JPY
Jan 1, 2016
140.00 M JPY
Jan 1, 2017
378.00 M JPY
Jan 1, 2018
544.00 M JPY
Jan 1, 2019
996.00 M JPY
The ReproCell Long-Term Investments history
YEARLong-Term InvestmentsYoY
996.00 MJPY+83.09%
544.00 MJPY+43.92%
378.00 MJPY+170.00%
140.00 MJPY+79.49%
78.00 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Long-Term Investments of ReproCell is 996.00 M JPY in 2019.

Long-Term Investments of ReproCell changed from 544.00 M JPY to 996.00 M JPY, representing a 83.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Investments ReproCell since 2006 – with annual values, charts, and detailed analysis.

Long-term investments include equity stakes, bonds, and other securities held for more than one year. They represent strategic or financial investments for future returns.

Long-Term Investments's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Investments's ReproCell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ReproCell

All Key Metrics — ReproCell